Targeting histone acetyltransferases (HATs) like EP300 and CREBBP, which catalyze H3K27ac, has emerged as a therapeutic strategy to modulate transcriptional programs implicated in CRC progression (266, 267). Here, EP300 is linked to colorectal carcinoma.